Adenoid hypertrophy with snoring and nasal congestion. Hypertrophy of adenoids
Conditions
Interventions
Intervention 1: in the case group betametason drop TDS two drop used in the nasal cavity and evaluation 1 to 3 Interval according obstractive and infectious symptome. Intervention 2: in the control gr
Treatment - Drugs
in the case group betametason drop TDS two drop used in the nasal cavity and evaluation 1 to 3 Interval according obstractive and infectious symptome
in the control group N/S drop TDS two drop used in the nasal cavity and evaluation 1 to 3 Interval according obstractive and infectious symptome
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
1 Years to 12 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: all of the infant 1-12 years with symptomatic adenoid hypertrophy without emergency indication surgery. Exclusion criteria: hypertrophy of adenoid with tonsil hypertrophy and indication emergency surgery.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Snoring. Timepoint: 1 , 3 month after treatment. Method of measurement: history and physical examination.;Change of facial bone. Timepoint: 1 , 3 month after treatment. Method of measurement: history and physical examination.;Mouth breath. Timepoint: 1 , 3 month after treatment. Method of measurement: history and physical examination.;Rhinorea. Timepoint: 1 , 3 month after treatment. Method of measurement: history and physical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Local and systemic compliction of bethamethason. Timepoint: One month after of intervention – 3 month after intervention. Method of measurement: Questionnaire sheet with clinical symptome. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed